Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RANDOMIZED TRIAL OF RIDOGREL, A COMBINED THROMBOXANE A(2) SYNTHASE INHIBITOR AND THROMBOXANE A(2) PROSTAGLANDIN ENDOPEROXIDE RECEPTOR ANTAGONIST, VERSUS ASPIRIN AS ADJUNCT TO THROMBOLYSIS IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - THE RIDOGREL VERSUS ASPIRIN PATENCY TRIAL (RAPT)/
Autore:
VANDEWERF F; SANTOPINTO J; CORDERO FA; FAINSTEIN D; CORINALDESI A; ZAVATTI D; LUPPI O; IPARRAGUIRRE HP; HIRSCHSON A; PIOMBO A; LAPUENTE A; KRITZER J; SAMPO E; AGINSKY R; TAJER C; CERCOS H; BALLESTRINI A; GUZMAN L; MELE E; BOND M; THOMPSON A; BAEFF O; CORTEZ A; RYBA D; LOWENSTEIN J; PENSA C; ZAMUZ A; LIMA RF; MARMONTI M; UBALDINI J; LOPEZ JG; BERRA FC; YANGUAS M; PALMA AL; CASTILLA J; CONCI E; GAVIER MD; BASTIANELLI R; VERGOTTINI J; BADARACCO R; SANJURJO M; SOSA C; VENTURA A; CARTASEGNA L; ABALDE J; TORRIJOS J; PERRINO O; ZOCCO J; MONTENEGRO D; CORSIGLIA D; RIGHETTI L; BADRA R; GARCIA M; ORTEGO R; HIDALGO J; ROMERO G; RODENAS P; ROSSI O; PUCCINI V; DIEZ A; LOCATELLI H; BRUERA E; ROBIOLO A; VILLARES J; CUNEO C; FALU E; BECKER C; MONGE A; MINEN O; CASANAS R; FERNANDEZ R; IBARZABAL U; SIRENA J; ALVAREZ A; CASTELLANOS R; MEULI M; ROMERO M; QUINTANA R; SOUSA JEMR; PIEGAS LS; AVEZUM A; TIMERMAN R; ROMANO ER; CARVALHO AC; FAELLI D; FARRAN J; NICOLAU JC; BRAGA J; SILVA JAF; BODANESE LC; RIMENTEL P; SANDOYA E; LLUBERAS R; AMARAL DC; RODRIGUEZ JC; DIAZ R; PAOLASSO E; VERCAMMEN E; BROWER R; FUSTER V; MURRAY G; TOPOL E; WHITE H; POLLOLA J; PAVIOTTI C; AIZPURUA M; GONZALEZ N; GUIRAO F; RODRIGUEZ A; SARMIENTO R; LONDERO H; SOUSA AGMR; PINTO IM; MOLTENI S; SCHWARTZ H; SZWARCER E; CANALA M; ESCALANTE L; AGGIO M; BARTOMIOLI M; GIULIANI R; MARELLO L; VIDAL H; ORLANDO S; WOODS A; NATTERO G; VILLAFANE S; LANARI E; GUTNISKY E; SAVARINO M; DEKROLLE S; DEPAOLETTI D; MARCIPAR D; HARRACA M; MORALES M; GENOVESI A; BAITCH L; SWING E; MANRIQUE R;
Indirizzi:
UNIV HOSP GASTHUISBERG,DIV CARDIOL,HEREST 49 B-3000 LOUVAIN BELGIUM ESTUDIOS CARDIOL LATINOAMER COORDINATING CTR BUENOS AIRES DF ARGENTINA UNIV LEUVEN LOUVAIN BELGIUM
Titolo Testata:
Circulation
fascicolo: 2, volume: 89, anno: 1994,
pagine: 588 - 595
SICI:
0009-7322(1994)89:2<588:RTORAC>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANINE CORONARY-ARTERIES; SYNTHETASE INHIBITION; PLASMINOGEN-ACTIVATOR; ONE MOLECULE; A2 SYNTHASE; BLOCKADE; PROSTACYCLIN; DISEASE; INVIVO; ACETYLCHOLINE;
Keywords:
STREPTOKINASE; PLATELETS; RIDOGREL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
F. Vandewerf et al., "RANDOMIZED TRIAL OF RIDOGREL, A COMBINED THROMBOXANE A(2) SYNTHASE INHIBITOR AND THROMBOXANE A(2) PROSTAGLANDIN ENDOPEROXIDE RECEPTOR ANTAGONIST, VERSUS ASPIRIN AS ADJUNCT TO THROMBOLYSIS IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - THE RIDOGREL VERSUS ASPIRIN PATENCY TRIAL (RAPT)/", Circulation, 89(2), 1994, pp. 588-595

Abstract

Background Aspirin, by nonselectively blocking cyclooxygenase both inplatelets and in endothelial cells, not only inhibits the thromboxaneA(2) pathway of platelet activation but at the same time also the generation of vasodilating and platelet-inhibitory prostanoids, such as prostacyclin, by the endothelial cells. Ridogrel, by inhibiting thromboxane A(2) synthase and blocking the thromboxane A(2)/prostaglandin endoperoxide receptors, is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis. This study was performed to compare the efficacy and safety of ridogrel with that of aspirin as conjunctive therapy for thrombolysis in patients with acute myocardial infarction. Methods and Results A total of 907 patients with acute myocardial infarction were randomized between aspirin and ridogrel given in addition to streptokinase (1.5 MU over a period of 1 hour). The primary end point was coronary patency (TIMI flow grades 2 and 3) at predischarge angiography to be performed between 7 and 14 days after admission. A patent infarct-related vessel was found in similar proportions of patients in the two treatment groups: 72.2% in the ridogrel and 75.5% in the aspirin group. The presence of clinical markers of reperfusion at 2 hours and the incidence of major clinical events during hospital stay were also similar in both groups. However, in a post hoc analysis, a lower incidence of new ischemic events (reinfarction, recurrent angina, ischemic stroke) was observed with ridogrel: 13% versus 19% in the aspirin group (a 32% reduction; P<.025). No excess of serious bleeding complications, including hemorrhagic stroke, was found. Conclusions Ridogrel is not superior to aspirin in enhancing the fibrinolytic efficacy of streptokinase but might bemore effective in preventing new ischemic events.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 03:26:37